Engineered Stem Cell Booster Breaks Pathological Barriers to Treat Chronic Pancreatitis

Area of Science:

• Regenerative Medicine
• Gastroenterology
• Biomedical Engineering

Background:

• Chronic pancreatitis (CP) is a progressive, fibrotic disease with limited treatment options.
• Mesenchymal stem cells (MSCs) exhibit anti-fibrotic properties but face delivery and microenvironment challenges in CP.
• Existing therapies for CP are insufficient, highlighting the need for innovative treatment strategies.

Purpose of the Study:

• To develop a novel mesenchymal stem cell (MSC)-based delivery system for enhanced chronic pancreatitis (CP) treatment.
• To overcome pathological barriers, including fibrotic collagen and hostile microenvironments, that limit MSC efficacy in CP.
• To investigate the therapeutic potential of a nitric oxide (NO)-releasing MSC system for pancreatic fibrosis.

Main Methods:

• Construction of a mesenchymal stem cell (MSC)-based nitric oxide (NO) delivery system (MSCs-Lip@RNO).
• Utilizing NO to modulate collagen fibers, alleviate vascular compression, and improve MSC accumulation in the pancreas.
• Evaluating the long-acting therapeutic effects of MSCs-Lip@RNO in a rat model of chronic pancreatitis (CP).

Main Results:

• The MSCs-Lip@RNO system effectively delivered MSCs by regulating collagen and relieving vascular compression.
• Nitric oxide (NO) acted as a cell booster, enhancing MSC accumulation and therapeutic efficacy.
• A single dose of the long-acting MSCs-Lip@RNO significantly reduced pancreatic injury and fibrosis within 7 days in a CP rat model.

Conclusions:

• The developed MSCs-Lip@RNO system offers a promising strategy to enhance MSC delivery and therapeutic efficacy for chronic pancreatitis (CP).
• This approach effectively breaks down pathological barriers, paving the way for improved treatments for fibroinflammatory diseases.
• The study demonstrates a novel method for improving stem cell-based therapies by addressing delivery and microenvironment challenges.